Assessing tumor angiogenesis using macromolecular MR imaging contrast media.
about
Design of ProCAs (protein-based Gd(3+) MRI contrast agents) with high dose efficiency and capability for molecular imaging of cancer biomarkersDesign of a novel class of protein-based magnetic resonance imaging contrast agents for the molecular imaging of cancer biomarkersPermeability imaging in pediatric brain tumors.Progress on the diagnosis and evaluation of brain tumors.Simultaneous mapping of blood volume and endothelial permeability surface area product in gliomas using iterative analysis of first-pass dynamic contrast enhanced MRI data.Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478.3D-micro-MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties.In vivo magnetic resonance methods in pharmaceutical research: current status and perspectives.Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma.Synthesis and evaluation of a polydisulfide with Gd-DOTA monoamide side chains as a biodegradable macromolecular contrast agent for MR blood pool imagingQuantitative analysis of intravenously administered contrast media reveals changes in vascular barrier functions in a murine colitis model.Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas.Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas.Imaging hypoxia in gliomas.High-field small animal magnetic resonance oncology studies.Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats.Molecular imaging using magnetic resonance: new tools for the development of tumour therapy.Analysis of dynamic contrast enhanced MRI.Measurement of kinetic parameters in skeletal muscle by magnetic resonance imaging with an intravascular agent.Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancerHypoxic stress and cancer: imaging the axis of evil in tumor metastasis.Gadolinium(III)-based blood-pool contrast agents for magnetic resonance imaging: status and clinical potential.Assessment of the early effects of 5,6-dimethylxanthenone-4-acetic acid using macromolecular contrast media-enhanced magnetic resonance imaging: ectopic versus orthotopic tumors.Acute vascular disruption by 5,6-dimethylxanthenone-4-acetic Acid in an orthotopic model of human head and neck cancer.Molecular Imaging of Cancer: Applications of Magnetic Resonance Methods.Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model.MR molecular imaging of tumor vasculature and vascular targets.AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer.Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments.Anti-angiogenic Effects of Bumetanide Revealed by DCE-MRI with a Biodegradable Macromolecular Contrast Agent in a Colon Cancer ModelApplication of ex vivo micro-computed tomography for assessment of in vivo fluorescence and plain radiographic imaging for monitoring bone metastases and osteolytic lesions.Radiolabeling optimization and characterization of (68)Ga labeled DOTA-polyamido-amine dendrimer conjugate - Animal biodistribution and PET imaging results.Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101.Investigation of longitudinal vascular changes in control and chemotherapy-treated tumors to serve as therapeutic efficacy predictors.A new polysaccharide macromolecular contrast agent for MR imaging: biodistribution and imaging characteristics.Is Weisskoff model valid for the correction of contrast agent extravasation with combined T1 and T2* effects in dynamic susceptibility contrast MRI?Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores.Characterization of carotid artery plaques with USPIO-enhanced MRI: assessment of inflammation and vascularity as in vivo imaging biomarkers for plaque vulnerability.Assessment of a rapid clearance blood pool MR contrast medium (P792) for assays of microvascular characteristics in experimental breast tumors with correlations to histopathology.
P2860
Q28235682-EDFBAFF5-BE12-4903-ABD3-DBDD2D7A3741Q28283802-DD25C52D-4122-494F-8B02-CD999F86E4EDQ30392559-6AD349DF-EDB5-4DED-BD9E-6170CEF618A5Q30714285-6A192CAB-DB95-495B-877B-02787C8FC809Q30770588-1ADB6EAE-4BFE-4412-A5FE-B3385E47879EQ30992467-57B20B0E-DEBE-4D2E-BD27-F19D4F904B6CQ32163028-7D72DCD8-608A-4C45-B960-C247E5DC344CQ33678501-D54FB939-172D-4A9A-8DAD-102399C3AD0EQ33744672-4AAEA010-4495-41D2-8BB4-F5E95C72B45BQ33768662-2F9E935B-0799-47A8-857B-7D2B30B7AFA0Q33799581-6EDAA6D7-8DB1-495F-813F-744E305788D8Q33847006-28B002D8-E2FA-4C7F-947B-B43F2BF8F274Q33989239-F6803153-45C4-4C8D-88E3-FD0DB60A85BFQ34133542-A3BF1AC4-4E9A-4262-9B6D-4FC32A0864A0Q34203937-1EBEB9CD-3362-4D09-B759-8E3F201B14D0Q35312455-3AF3933E-4D10-4AE6-933B-853E891A93E5Q35581064-0CA5F3A9-ACF8-4978-8A16-18781B59CF98Q35968106-49B6E4D3-E64E-4B8B-A1B3-2B1838E9E175Q36022692-1ED3BE48-3381-44E2-BAB1-BB9635341B3EQ36091932-66D23F2B-3F48-4F19-8343-73FCB0251C11Q36104744-EB558E4D-CFD4-468E-9D15-8D0391F2EAD4Q36573025-39CCE521-CA95-4C8A-B883-54583378AAA3Q36750157-EC465742-0337-4749-83B9-F237651F9220Q36972860-34EC0EF5-641D-4719-8963-C5DCE747D099Q37313683-FF8B4D6A-240D-4B83-9CD4-BF32EA5A6F22Q37359297-465DC03A-2EEC-4642-AC7B-0D2F4BD0559EQ37417880-947D6049-7A46-4242-A6D4-BC9242613583Q37784288-4333E499-CE67-441A-957E-11DAE6B5520EQ37826430-B98041C6-AA56-45D1-BA84-C67F2FDCC6DBQ38168371-A0B15B29-A514-4E6F-A8D8-87CBE67840DFQ38891146-B5411CA9-3B26-42C8-AF70-10139BF83BA0Q39435048-35C5779B-846F-4535-A373-4A4958C09B0CQ40671172-36CAC598-CFE5-4CCC-BA3B-159DA75F0BCFQ41559635-8CC9E293-07FC-45E6-83DE-8B9F96100345Q41609320-DA078D53-53DD-4687-868C-AF754F5E29F7Q41742671-8464DF3B-29FF-455B-8B92-6E5EE32EEE3FQ43673888-3FCEA139-5263-409B-96BD-9D11979A0D9DQ43825494-B10A3A4D-15F6-4DE5-84E4-B025E93479FDQ45739358-C712CF75-A1BA-458C-9A25-58CF900C03B9Q46103337-DF2D7BE7-762C-42B1-B22B-531462C87D2F
P2860
Assessing tumor angiogenesis using macromolecular MR imaging contrast media.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Assessing tumor angiogenesis using macromolecular MR imaging contrast media.
@en
type
label
Assessing tumor angiogenesis using macromolecular MR imaging contrast media.
@en
prefLabel
Assessing tumor angiogenesis using macromolecular MR imaging contrast media.
@en
P2093
P2860
P356
P1476
Assessing tumor angiogenesis using macromolecular MR imaging contrast media
@en
P2093
K van Dijke
N van Bruggen
S Ostrowitzki
P2860
P356
10.1002/JMRI.1880070110
P577
1997-01-01T00:00:00Z